Doravirine
Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.
Clinical data | |
---|---|
Trade names | Pifeltro |
Other names | MK-1439 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618048 |
License data |
|
Routes of administration | By mouth[1][2] |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.234.454 |
Chemical and physical data | |
Formula | C17H11ClF3N5O3 |
Molar mass | 425.75 g·mol−1 |
3D model (JSmol) | |
| |
|
Doravirine was approved for medical use in the United States in August 2018.[5]
References
- "Pifeltro- doravirine tablet, film coated". DailyMed. 10 October 2019. Retrieved 22 September 2020.
- Collins S, Horn T. "The Antiretroviral Pipeline" (PDF). Pipeline Report. p. 10. Archived from the original (PDF) on 11 March 2016. Retrieved 6 December 2015.
- "Pifeltro 100 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 1 October 2020.
- "Pifeltro EPAR". European Medicines Agency (EMA). Retrieved 1 October 2020.
- "Drug Approval Package: Pifeltro (doravirine)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 22 September 2020.
External links
- "Doravirine". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.